SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Google

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Treatment hope for cognitive symptoms in Parkinson's disease
Tues May 17th - Ultra-powerful 7T MRI scanners could help to identify those patients with conditions such as Parkinson's disease who would benefit from new treatments for cognitive symptoms that were previously untreatable, British researchers report today. More
E-cigarettes as effective as patches for pregnant women
Tues May 17th - E-cigarettes can help pregnant women to stop smoking and are as safe as nicotine patches, according to new UK research. More
RECENT COMMENTS
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

Promising portable device for at-home skin cancer treatment

Monday October 4th 2021

A home device has been developed that can reduces pain levels during basal cell carcinoma treatment - while achieving results as good as those as a hospital stay, a conference has heard.

The coin-sized prototype photodynamic therapy (PDT) device has been tested in a pilot study in Brazil. The results were presented at the European dermatology EADV Congress 2021.

Although PDT, which involves light-sensitive medicine and a light source to destroy abnormal cancer cells, for low-risk BCC has been proven through multiple studies, the need to reduce pain during treatment and a long hospital stay led to the development of a new device.

Standard PDT treatment consists of two sessions performed within a hospital environment that usually requires a 1.5-two hour wait with a one-week interval.

The pilot study involved 15 BCC patients at Amaral Carvalho Hospital with Sao Carlos Institute of Physics, in Sao Paulo State.

The first PDT session was at the hospital, where a 20% methyl aminolevulinate cream was applied to the BCC lesion before being illuminated for 20 minutes with a commercial red light LED device.

Immediately after the first illumination, a light layer of cream was applied and the new portable irradiation device was fixed to the skin using medical tape.

The patient was then sent home and told to turn on the illumination after 90 minutes and switch it off after two hours.

Pain was assessed every three minutes during the hospital PDT treatment session and self-reported every 20 minutes during home treatment, with the median score values compared between hospital and home treatments.

Analysis found the clearance at 30 days after PDT was 86.67%, which is similar to standard PDT treatment.

The pain score was significantly lower for the PDT treatment performed at home – self-reported by the patients as a one for the first three measures and a zero for the four – compared to three-four for the hospital treatment.

Lead study author Ana Gabriela Salvio said: “Our study results could have a hugely positive impact on the treatment of basal cell carcinoma in Brazil and the rest of the world.

“Patients reporting much lower levels of pain from the at-home treatment is really encouraging, especially because it doesn’t come at the cost of efficacy.”

A clinical trial with more than 200 participants has now been approved.

Salvio AG, Requenna MB, Stringasci M et al. Photodynamic Therapy performed at home: The use of a portable device to decrease the patient’s stay at hospital without compromising the efficacy of basal cell carcinoma treatment; Abstract no. 1289, submitted to EADV 30th Congress, 29-02 October 2021

Tags: Cancer | Dermatology | Europe | South America

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES